Skip to main content
main-content

01.12.2010 | Research | Ausgabe 1/2010 Open Access

Journal of Inflammation 1/2010

Inhibition of allogeneic inflammatory responses by the Ribonucleotide Reductase Inhibitors, Didox and Trimidox

Zeitschrift:
Journal of Inflammation > Ausgabe 1/2010
Autoren:
Mohammed S Inayat, Ismail S El-Amouri, Mohammad Bani-Ahmad, Howard L Elford, Vincent S Gallicchio, Oliver R Oakley
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1476-9255-7-43) contains supplementary material, which is available to authorized users.

Competing interests

HE is President and a shareholder of Molecules for Health (MFH) and thereby has a financial interest in Didox or Trimidox therapeutic potential. All other authors declare that they have no competing interests.

Authors' contributions

MI participated in the design of the experiments, carried out the T-cell isolation, T-cell proliferation, cytokine analysis and MLR and analysis of the data. IE participated in the T-cell proliferation assays and statistical analysis. MB participated in the T-cell proliferation assays. HE supplied the compounds Trimidox and Didox and participated in the determination of the in vitro dosing. VG assisted in drafting the manuscript. OO conceived the study, directed its design and coordination and drafted the manuscript. All authors read and approved the final manuscript.

Abstract

Background

Graft-versus-host disease is the single most important obstacle facing successful allogeneic stem cell transplantation (SCT). Even with current immunosuppressive therapies, morbidity and mortality rates are high. Current therapies including cyclosporine A (CyA) and related compounds target IL-2 signaling. However, although these compounds offer great benefit, they are also associated with multiple toxicities. Therefore, new compounds with a greater efficacy and reduced toxicity are needed to enable us to overcome this hurdle.

Methods

The allogeneic mixed lymphocyte reaction (MLR) is a unique ex vivo method to study a drug's action on the initial events resulting in T-cell activation and proliferation, synonymous to the initial stages of tissue and organ destruction by T-cell responses in organ rejection and Graft-versus-host disease. Using this approach, we examined the effectiveness of two ribonucleotide reductase inhibitors (RRI), Didox and Trimidox, to inhibit T-cell activation and proliferation.

Results

The compounds caused a marked reduction in the proliferative responses of T-cells, which is also accompanied by decreased secretion of cytokines IL-6, IFN-γ, TNF-α, IL-2, IL-13, IL-10 and IL-4.

Conclusions

In conclusion, these data provide critical information to justify further investigation into the potential use of these compounds post allogeneic bone marrow transplantation to alleviate graft-versus-host disease thereby achieving better outcomes.
Zusatzmaterial
Authors’ original file for figure 1
12950_2010_162_MOESM1_ESM.pdf
Authors’ original file for figure 2
12950_2010_162_MOESM2_ESM.pdf
Authors’ original file for figure 3
12950_2010_162_MOESM3_ESM.pdf
Authors’ original file for figure 4
12950_2010_162_MOESM4_ESM.pdf
Authors’ original file for figure 5
12950_2010_162_MOESM5_ESM.pdf
Authors’ original file for figure 6
12950_2010_162_MOESM6_ESM.pdf
Authors’ original file for figure 7
12950_2010_162_MOESM7_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2010

Journal of Inflammation 1/2010 Zur Ausgabe


 

Neu im Fachgebiet Innere Medizin

Meistgelesene Bücher aus der Inneren Medizin

2017 | Buch

Rheumatologie aus der Praxis

Entzündliche Gelenkerkrankungen – mit Fallbeispielen

Dieses Fachbuch macht mit den wichtigsten chronisch entzündlichen Gelenk- und Wirbelsäulenerkrankungen vertraut. Anhand von über 40 instruktiven Fallbeispielen werden anschaulich diagnostisches Vorgehen, therapeutisches Ansprechen und der Verlauf …

Herausgeber:
Rudolf Puchner

2016 | Buch

Ambulant erworbene Pneumonie

Was, wann, warum – Dieses Buch bietet differenzierte Diagnostik und Therapie der ambulant erworbenen Pneumonie zur sofortigen sicheren Anwendung. Entsprechend der neuesten Studien und Leitlinien aller wichtigen Fachgesellschaften.

Herausgeber:
Santiago Ewig

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin 

Bildnachweise